Business Wire

Budweiser Heralds the Return of FIFA World Cup™ With Global Campaign Declaring “The World is Yours to Take”

Share

Budweiser, an Anheuser-Busch InBev (AB InBev) (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD) brand and FIFA World Cup™ Sponsor, has debuted a global rallying-cry for fans: “The World is Yours to Take.” In partnership with international football icons Lionel Messi, Neymar Jr., and Raheem Sterling, Budweiser will launch its FIFA World Cup campaign in more than 70 countries, the most in the brand’s 146-year history.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220915005360/en/

The campaign is anchored by a cinematic film featuring the athletes and a diverse group of fans making their way through the player’s tunnel with conviction toward the FIFA World Cup pitch. The spot cleverly uses the tunnel as a metaphor to connect fans to the emotion and anticipation the players feel before the match, inspiring them to take the next step in their journey towards pursuing their dreams. The soundtrack of the campaign is a reimagining of the iconic Tears for Fears’ anthem “Everybody Wants to Rule the World,” capturing the passion and enthusiasm fans will feel during this year’s tournament.

“As sponsor of the FIFA World Cup for more than 30 years, we wanted to capture the infectious global energy of football fans everywhere to encourage people to find the conviction to go for greatness, no matter what the journey to get there might look like,” said Todd Allen, Global Vice President of Marketing, Budweiser. “Determination to overcome challenges in the name of achieving greatness, like we’ve seen countless times from Messi, Neymar Jr., and Sterling, is an inspiration to us and to fans around the world. We hope our new campaign reminds fans that no matter what stands in your way, the world is yours to take.”

In this global campaign, Budweiser has created new avenues for fans to experience the FIFA World Cup both on the ground and at home including: the chance to win match tickets by scanning QR codes found on limited-edition Budweiser bottles and cans, attending BUDX FIFA Fanfest watch parties around the world for the first time, on-site activations and musical performances at the Budweiser Hotel and NFTs that commemorate the world’s biggest sporting event.

Additionally, Budweiser will tap into the global scale of AB InBev DTC & B2B platforms by delivering cold beer to fans in under 30 minutes (in select markets where available) before match kick-off and excite retail partners by creating unique activations through BEES in over 1 million locations where Budweiser is sold.

The Budverse x FIFA World Cup NFT Collection will be available to consumers of legal drinking age via two different token types at launch – the Budweiser Live Scoreboard and the Budweiser World Cup 360 Experience. To learn more about the Budverse x FIFA World Cup Collection, visit Budweiser.com/nft.

The campaign film was developed in partnership with creative agency Wieden+Kennedy and is an evolution of Budweiser’s new “Yours to Take” platform launched earlier this year.

To view the new spot, visit Budweiser’s YouTube channel.

About Anheuser-Busch InBev and Budweiser

Anheuser-Busch InBev is a publicly traded company (Euronext: ABI) based in Leuven, Belgium, with secondary listings on the Mexico (MEXBOL: ANB) and South Africa (JSE: ANH) stock exchanges and with American Depositary Receipts on the New York Stock Exchange (NYSE: BUD). As a company, we dream big to create a future with more cheers. We are always looking to serve up new ways to meet life’s moments, move our industry forward and make a meaningful impact in the world. We are committed to building great brands that stand the test of time and to brewing the best beers using the finest ingredients. Our diverse portfolio of well over 500 beer brands includes global brands Budweiser®, Corona® and Stella Artois®; multi-country brands Beck’s®, Hoegaarden®, Leffe® and Michelob ULTRA®; and local champions such as Aguila®, Antarctica®, Bud Light®, Brahma®, Cass®, Castle®, Castle Lite®, Cristal®, Harbin®, Jupiler®, Modelo Especial®, Quilmes®, Victoria®, Sedrin®, and Skol®. Our brewing heritage dates back more than 600 years, spanning continents and generations. From our European roots at the Den Hoorn brewery in Leuven, Belgium. To the pioneering spirit of the Anheuser & Co brewery in St. Louis, US. To the creation of the Castle Brewery in South Africa during the Johannesburg gold rush. To Bohemia, the first brewery in Brazil. Geographically diversified with a balanced exposure to developed and developing markets, we leverage the collective strengths of approximately 169,000 colleagues based in nearly 50 countries worldwide. For 2021, AB InBev’s reported revenue was 54.3 billion USD (excluding JVs and associates).

Budweiser is a medium-bodied, flavorful, crisp American-style lager. Brewed with the best barley mallet and a blend of premium hop varieties, Budweiser is an icon of optimism and celebration which is enjoyed in over 60 countries around the world and is committed to brewing every Budweiser with 100% renewable electricity.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
Budweiser / AB InBev
media.relations@ab-inbev.com

Allison+Partners
BudGlobal@allisonpr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

4P-Pharma Announces Total Capital of €15 Million Successfully Secured in Second Closing29.4.2024 07:40:00 EEST | Press release

4P-Pharma, a Lille-based clinical-stage startup studio focused on developing curative therapies for untreated serious diseases, announces that it has successfully secured a total capital of €15 million in its second closing with participation from private investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424933193/en/ (Graphic: Business Wire) With this funding, 4P-Pharma's shareholders renew their confidence in the company's drug regeneration model for untreated serious diseases. They welcome the entry of Phase 2 clinical development of the two first 4P-Pharma's SPVs, underlying the robust potential of the company's business model. Revital Rattenbach, CEO of 4P-Pharma: "As CEO of 4P-Pharma, I am pleased with the renewed trust of our investors placed in our scientific and development approach year after year. This financial endorsement underscores our significant progress over the past decade. It attests to the str

PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA29.4.2024 07:17:00 EEST | Press release

PROTEINA announced today that it has held a kickoff meeting with Professor Janghee Woo and his research team at Emory University School of Medicine in Atlanta, to begin global clinical validation of its flagship product, PPI PathFinder BCL2 Dx. PPI PathFinder BCL2 Dx incorporates PROTEINA’s “SPID (Single-molecule Protein Interaction Detection)” technology, enabling high-sensitivity detection of protein-protein interaction (PPI) complexes of BCL2 family proteins and more accurate prediction of any PPI inhibitors targeting the BCL2 family. In this clinical validation, PPI PathFinder BCL2 Dx will be used to predict drug responsiveness in patients with Acute Myeloid Leukemia (AML), providing clinicians with guidance for more effective prescriptions of the widespread BCL2-targeted cancer drug “Venetoclax.” PROTEINA has previously conducted clinical validation of the same product domestically with the Hematologic Cancer Team at Seoul National University, and the findings are scheduled to be

TUM Races to Victory at ASPIRE’s Inaugural Abu Dhabi Autonomous Racing League at Yas Marina Circuit28.4.2024 14:57:00 EEST | Press release

TUM (Technical University of Munich) from Germany, claimed victory at the inaugural Abu Dhabi Autonomous Racing League (A2RL), at Yas Marina Circuit on Saturday (April 27). As the cars lined up on the grid, with antennae, sensors, AI capabilities, and drive-by-wire systems instead of human drivers, eight teams vied with one another over two days of races and challenges. TUM beat back the competition with its coding and engineering skills in a world-first, four-car race finale, to claim the winner’s share of US$2.25 million prize pot. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240428292385/en/ TUM Races to Victory at ASPIRE’s Inaugural Abu Dhabi Autonomous Racing League at Yas Marina Circuit - (Photo: AETOSWire) Bringing a science experiment to the racetrack, the inaugural race pushed the boundaries of autonomous technology while adding entertainment value to extreme sports at an unprecedented scale. A2RL drew over 10,000

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 03:09:00 EEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio ha

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 23:06:00 EEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye